Skip to main content
OpenTrials
Completed

NCT Number: NCT06581263

Psychedelic Virtual Reality

The purpose of this study is to evaluate a novel VRP.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psychedelic Experiences Healthy Volunteer Virtual Reality

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Yale University School of Medicine

New Haven, Connecticut, 06510, United States

About this study

The primary objective of this study is to determine whether the subjective experience of a novel VRP (DeepDream) will be comparable to a standard dose of psychedelics. This study also looks to compare the subjective experience of DeepDream VRP to other available VR modalities developed to mimic psychedelic subjective experience along with assessing the incidence of VRP adverse effects.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability to provide informed consent
  • No history or current DSM-V diagnosis

Exclusion criteria

  • Unstable medical conditions

Treatment and study plan

Meta Quest 3

Device

Meta Quest 3 is a virtual reality headset device

Primary outcomes

  1. Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.

    Time frame: Day 0 through Day 30

    Subject experience will be assessed using the Altered States of Consciousness Rating Scale.

  2. Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.

    Time frame: Day 0 through Day 30

    Subject experience will be assessed using the Mystical Experience Questionnaire.

  3. Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.

    Time frame: Day 0 through Day 30

    Subject experience will be assessed using the Ego-Dissolution Inventory.

Secondary outcomes

  1. Assess the incidence of VRP adverse effects, principally virtual reality sickness (VRS) and neck and upper back pain.

    Time frame: Day 0 through Day 30

    The number of adverse events will be assessed through qualitative interviews following VRP viewing.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Registry information

Official study title

Investigating the Use of Virtual Reality in Psychedelic Research or Clinical Practice

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 3, 2024
Registry last updated
Mar 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.